Isracann Biosciences Inc. (ISCNF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.75 Million | -4.22 Million | -10.4 Million | -2.94 Million | -2.93 Million |
| Net Income | - | -4.69 Million | -25.12 Million | -23.91 Million | -5.59 Million | -7.47 Million |
| Depreciation & Amortization | - | 41.73 Thousand | 41.3 Thousand | 45.12 Thousand | 44.84 Thousand | 584.41 Thousand |
| Deferred income taxes | - | 2.22 Million | 31.03 Thousand | -68.5 Thousand | - | 1 Million |
| Stock-based compensation | - | 56.74 Thousand | 739.11 Thousand | 1.17 Million | 1.16 Million | - |
| Change in working capital | - | 694.21 Thousand | -62.83 Thousand | 113.12 Thousand | 72.2 Thousand | 190.38 Thousand |
| Other non-cash items | - | -79.57 Thousand | 20.14 Million | 12.25 Million | 1.37 Million | -562.04 Thousand |
| Investing Cash Flow | - | -77.15 Thousand | 133.65 Thousand | -2.63 Million | -856.71 Thousand | -5.98 Million |
| Investments in PPE | - | - | -13.68 Thousand | -508.93 Thousand | -203.71 Thousand | -5.98 Million |
| Acquisitions | - | 39.45 Thousand | 284.88 Thousand | 34.24 Thousand | -29.8 Thousand | - |
| Investment purchases | - | -116.6 Thousand | - | -1.65 Million | - | - |
| Sales/Maturities of investments | - | - | - | 508.93 Thousand | - | - |
| Other Investing Activities | - | -116.6 Thousand | -137.54 Thousand | -1.01 Million | -623.19 Thousand | - |
| Financing Cash Flow | - | 129.91 Thousand | 2.16 Million | 12.75 Million | 10.15 Million | 16.67 Million |
| Debt repayment | - | - | - | - | - | -13.24 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 129.91 Thousand | 2.17 Million | 2.81 Million | 10.15 Million | 3.42 Million |
| Other Financing Activities | - | - | -9771.00 | 9.94 Million | - | - |
| Accounts receivables | - | 213.48 Thousand | 126.62 Thousand | -58.9 Thousand | -106.02 Thousand | -2150.00 |
| Accounts payables | - | 444.4 Thousand | -285.96 Thousand | -80.48 Thousand | 63.02 Thousand | 802.35 Thousand |
| Inventory | - | - | 285.96 Thousand | 80.48 Thousand | -63.02 Thousand | - |
| Other working capital | - | 36.32 Thousand | -189.46 Thousand | 172.02 Thousand | 178.23 Thousand | 192.53 Thousand |
| Cash at beginning of period | 213.93 Thousand | 1.95 Million | 3.89 Million | 4.17 Million | 7.97 Million | 223.62 Thousand |
| Cash at end of period | 213.93 Thousand | 213.93 Thousand | 1.95 Million | 3.89 Million | 4.17 Million | 7.97 Million |
| Capital Expenditure | - | - | -13.68 Thousand | -508.93 Thousand | -203.71 Thousand | -5.98 Million |
| Effect of forex changes on cash | - | -42.67 Thousand | -2049.00 | -9934.00 | -10.15 Million | - |
| Net cash flow / Change in cash | - | -1.74 Million | -1.93 Million | -286.88 Thousand | -3.8 Million | 7.75 Million |
| Free Cash Flow | - | -1.75 Million | -4.24 Million | -10.9 Million | -3.14 Million | -8.92 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | -315.99 Thousand |
| Depreciation & Amortization | - | - | - | - | - | 10.43 Thousand |
| Deferred income taxes | - | - | - | - | - | 11.44 Thousand |
| Stock-based compensation | - | - | - | - | - | 3538.00 |
| Change in working capital | - | - | - | - | - | 128.63 Thousand |
| Other non-cash items | - | - | - | - | - | -1450.00 |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | 151.55 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 104.07 Thousand |
| Other Financing Activities | - | - | - | - | - | 47.48 Thousand |
| Accounts receivables | - | - | - | - | - | -9019.00 |
| Accounts payables | - | - | - | - | - | 112.45 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | 25.19 Thousand |
| Cash at beginning of period | - | - | 213.93 Thousand | - | 198.05 Thousand | 213.93 Thousand |
| Cash at end of period | - | - | 213.93 Thousand | - | 198.05 Thousand | 198.05 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | -4031.00 |
| Net cash flow / Change in cash | - | - | - | - | - | -15.88 Thousand |
| Free Cash Flow | - | - | - | - | - | -163.4 Thousand |
1407
SCM
SLTTF
ACLX
603788
9386